• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 26th July 2018

Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations? In the pharmaceutical industry, intellectual property (IP) rights protection, including patents, data exclusivity (DE), and Supplementary Protection Certificates (SPCs), is seen…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?

In the pharmaceutical industry, intellectual property (IP) rights protection, including patents, data exclusivity (DE), and Supplementary Protection Certificates (SPCs), is seen as important. This is due to the high cost of research and development (R&D) for new medicines and the issue of appropriability, a concept that reflects innovators’ capacity to capture or appropriate the added value created by successful innovation.
 
Problems can arise if the amount of appropriation is too low or too high. A low degree of appropriability could result in dynamic inefficiency or a suboptimal (too low) investment in innovation. However, too much IP protection might grant the originator market power for an excessive period. Such market power enables prices above manufacturing and distribution cost to give a return on R&D, but results in static inefficiency, whereby innovative medicines are not used by some patients, countries, or systems. Quantities sold are lower than the quantity that would maximise social welfare, given the existence of the product.
 
Our latest Research Paper contributes to this debate by analysing the functioning of a specific market for innovative treatments, Direct Acting Antivirals (DAAs) for hepatitis C virus (HCV), in six European countries. The authors explore the potential for in-class competition for DAAs to offset innovators’ market power and maximise the social welfare generated by the adoption of pharmaceutical innovation. A market characterised by a high degree of in-class competition while products are still on patent (IP-protected) would improve the affordability of medicines for governments and facilitate access and uptake to patients via prices. IP protection may increase this competition.
 
Using a multidisciplinary approach, combining a theoretical economic framework with uptake and market share analyses and interviews, the research assesses the impact of (i) incentives for R&D based on providing intellectual property (IP) rights protection; (ii) market competition; and (iii) other factors, including healthcare policies, on access to DAAs in Europe. 
 
Theoretical models show that current R&D incentives based on IP protection in the EU may have encouraged in-patent competition. In-patent DAA competition leads to price reductions that make new medicines more affordable and generate savings to payers via increased market power and capacity for surplus extraction. 
 
In the uptake analyses, the authors identify three different stages of market competition for DAAs in European countries. Analyses show that competition within the DAA class was intense, especially during the second stage when various options fought to gain market share. Uptake curves and market shares demonstrate that access to DAAs was sped up in this second stage for Germany, Spain, Italy and Portugal. For France, access was already high at this point, due to compassionate use, while the UK implemented restrictions on use.
 
Evidence from our interviews suggested that in-class competition improved access and uptake and provided bargaining power to payers. Improved characteristics of DAAs compared with interferon-based treatments, in terms of response rate and side effects, influenced access, as did their acceptable cost-effectiveness. Our estimates of health gains showed that countries relying on market competition, providing full access to all DAAs available and negotiating prices, accrued higher QALY gains from DAAs as compared to those implementing restrictions to control total expenditure on DAAs (such as the case of the UK until 2016).
 
Our paper concludes that IP incentives for R&D may have encouraged a high degree of in-class competition of DAAs close to the first entrant launch. In-class competition had a positive impact on uptake and adoption of DAAs in the top-5 European countries. However, in-class competition is a necessary but not sufficient condition for early adoption and fast uptake of innovative medicines as there are other factors related to the performance of the new technology, characteristics of the healthcare system and political factors, which can have an effect. 
 
Download the full report here.
 
Citation
 
Berdud, M., Garau, M., Neri, M., O’Neill, P., Sampson, C. and Towse, A. (2018). R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C. OHE Research Paper 18/06, London: Office of Health Economics. | RePEc
 
Related research
 
Danzon, P., Towse, A. and Mestre‐Ferrandiz, J., (2015). Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context. Health Economics, 24 (3), 294-301. | DOI | RePEc
 
Hampson, G., Towse, A. and Henshall, C. (2017). Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies. OHE Briefing. London: Office of Health Economics. | RePEc
 
Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., (2018). Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in Health, 21(3), pp.76-279. | DOI

 

  • Drug Development/R&D
  • Economics of Innovation
  • Competition

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!